Nektar Therapeutics Q3 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst : This is Daniel for Jessica Fye. Staying with 255, you stated that you're going in colorectal cancer in head and neck initially in solid tumors. Can you help us think about the opportunity of 255 in solid tumors? Why you're able to choose those 2 different tumor types? And then do you see combination as an ideal approach for this program as you advance it forward? Or is there an opportunity to evaluate it as a monotherapy as well?

Question: George Farmer - BMO Capital Markets Equity Research - Analyst : Wei, can you comment a bit on what the bar for success would be in PROPEL? 30 patients that are basically going to be distributed among different PD-L1 subgroups, are you expecting to see any differences there? And I know 30 patients is a good number to hit, but it's spread across all these different subgroups. It might get a little thin per subgroup. And then, JZ, I know there was some discussion about this yesterday. But could you talk about the significance of the CLASI-A score and how that relates to SLEDAI score in lupus and how we can think about the 2 different scoring systems?

Question: Arlinda Anna Lee - Canaccord Genuity Corp., Research Division - Analyst : On 358, given the potentially broad applicability of the Treg mechanism that you're (inaudible) presented yesterday, I'm kind of curious about how you guys chose the first 2 indications. And is there a sense to explore others as well? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 05, 2020 / 10:00PM, NKTR.OQ - Q3 2020 Nektar Therapeutics Earnings Call